Authors: Chiara Cremolini, Carlotta Antoniotti, Sara Lonardi, et. al. Abstract: 3508 Clinical Trial Registry Number: NCT02339116 Citation: J Clin Oncol 37, 2019 (suppl; abstr 3508) Background: In the phase III TRIBE study FOLFOXIRI/bev significantly improved Response Rate (RR), PFS and OS when compared with FOLFIRI/bev as initial treatment of mCRC. However,...
Pro zobrazení tohoto obsahu je třeba být přihlášen.